Cellular DNA and other nucleophilic biomolecules (DNA)

Cellular DNA and other nucleophilic biomolecules serve as the primary therapeutic targets for alkylating agents and platinum-based chemotherapeutics. These agents function as strong electrophiles that react covalently with nucleophilic moieties such as amino, carboxyl, sulfhydryl, and phosphate groups found on proteins and nucleic acids (StatPearls, 2023). The most critical pharmacological interaction occurs at the N7 position of guanine in DNA, leading to the formation of DNA adducts and cross-links that physically obstruct the machinery required for DNA replication and transcription (NCBI: Cancer Medicine). This disruption activates DNA damage response pathways, ultimately forcing the cell into programmed cell death or apoptosis (PubMed, PMID: 25613523). While DNA is the most significant target for anti-tumor efficacy, the non-specific reaction of these drugs with other cellular nucleophiles contributes to their broad toxicity profile (PubChem). Because these interactions are not specific to malignant cells, they frequently impact rapidly dividing healthy tissues, resulting in characteristic side effects such as bone marrow suppression and potential long-term risks like secondary cancers (NIH: National Cancer Institute).

Other names

Genomic DNANuclear DNACellular nucleophilesNucleophilic cellular constituentsDeoxyribonucleic acid

Drugs targeting these molecules act as electrophiles that form covalent bonds with nucleophilic centers, particularly the N7 position of guanine residues in DNA, resulting in DNA adducts, intra-strand cross-links, and inter-strand cross-links that inhibit replication and trigger apoptosis (StatPearls: Alkylating Agents, 2023; NCBI: Cancer Medicine).